Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 29 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors at 13 institutions in 6 countries.
Katharigatta N VenugopalaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0003-0680-1549
Sandeep ChandrashekharappaDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER-R) Raebareli, Lucknow UP 226002, India.ORCID 0000-0003-2475-7270
Christophe TratratDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Pran Kishore DebFaculty of Pharmacy, Philadelphia University, Amman 19392, Jordan.ORCID 0000-0002-8650-2874
Rahul D NagdeveDepartment of Chemistry, Visvesvaraya National Institute of Technology, Nagpur 440010, Maharashtra, India.ORCID 0000-0001-9695-0833
Susanta K NayakDepartment of Chemistry, Visvesvaraya National Institute of Technology, Nagpur 440010, Maharashtra, India.
Mohamed A MorsyDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-6752-9094
Pobitra BorahPratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati 781026, Assam, India.ORCID 0000-0003-1047-4552
Fawzi M MahomoodallyDepartment of Health Sciences, Faculty of Medicine and Health Sciences, University of Mauritius, Réduit 80835, Mauritius.ORCID 0000-0003-3962-8666
Raghu Prasad MailavaramDepartment of Pharmaceutical Chemistry, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram 534202, India.
Mahesh AttimaradDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-7007-9119
Bandar E AldhubiabDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-2684-4186
Nagaraja SreeharshaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-2058-255X
Anroop B NairDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0003-2850-8669
Osama I AlwassilDepartment of Pharmaceutical Sciences, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia.ORCID 0000-0002-6572-8321
Michelyne HarounDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Viresh MohanlallDepartment of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa.ORCID 0000-0002-0103-7089
Pottathil ShinuDepartment of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Rashmi VenugopalaDepartment of Public Health Medicine, Howard College Campus, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0002-1101-4577
Mahmoud KandeelDepartment of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0003-3668-5147
Belakatte P NandeshwarappaDepartment of Studies in Chemistry, Shivagangotri, Davangere University, Davangere, Karnataka 577007, India.
Yasmine F IbrahimDepartment of Pharmacology, Faculty of Medicine, Minia University, El-Minia 61511, Egypt.
King Faisal University · SADurban University of Technology · ZAVisvesvaraya National Institute of Technology · INDavangere University · INHindu College of Pharmacy · INInstitute for Stem Cell Biology and Regenerative Medicine · INKafrelsheikh University · EGKing Saud bin Abdulaziz University for Health Sciences · SAMinia University · EGPhiladelphia University · JOPratiksha Institute of Pharmaceutical SciencesUniversity of KwaZulu-Natal · ZAUniversity of Mauritius · MU
Funding
Deanship of Scientific Research, King Faisal University 186333
6 · The paper itself
Abstract
The cyclooxygenase-2 (COX-2) enzyme is an important target for drug discovery and development of novel anti-inflammatory agents. Selective COX-2 inhibitors have the advantage of reduced side-effects, which result from COX-1 inhibition that is usually observed with nonselective COX inhibitors. In this study, the design and synthesis of a new series of 7-methoxy indolizines as bioisostere indomethacin analogues (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Crystallography, Molecular Modeling, and COX-2 Inhibition Studies on Indolizine Derivatives. · full record | OpenQuestion